Janssen Belgium

XO1 Ltd is a biotechnology company focused on developing ichorcumab, an innovative anti-thrombin antibody designed to prevent heart attacks and strokes without the risk of bleeding. Operating as a virtual company, XO1 does not maintain physical office or laboratory space; instead, it collaborates with skilled contract research and development specialists across Europe and the United States. This model allows for efficient cost management and the flexibility to select the most suitable suppliers for specific tasks. The company aims to create a breakthrough anticoagulant drug that mimics the activity of a natural human antibody, offering a promising solution to the challenges associated with existing anticoagulant therapies.

Quanticare Technologies develops a sensor system for walking frames to prevent falls for seniors.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.

Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany. The company specializes in creating innovative therapeutics and diagnostics aimed at treating heart and vascular diseases, particularly those that currently have unmet medical needs. Corimmun's expertise encompasses the entire spectrum of drug development, from initial research through to commercialization, positioning it as a key player in the field of cardiovascular therapeutics.

Vertex Pharmaceuticals is a biotechnology company focused on discovering and developing small-molecule drugs for serious diseases. The company is particularly known for its therapies for cystic fibrosis, including Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, which are recognized as the standard of care globally. In addition to its cystic fibrosis portfolio, Vertex is advancing its capabilities in gene-editing therapies with Casgevy, aimed at treating beta thalassemia and sickle-cell disease. The company is also exploring small-molecule inhibitors for acute and chronic pain, as well as treatments for APOL1-mediated kidney diseases. Vertex's approach includes both independent commercialization and strategic collaborations with major pharmaceutical firms, underscoring its commitment to addressing unmet medical needs across several therapeutic areas, including viral diseases, inflammation, autoimmune diseases, cancer, and pain management.